+143.3%
MRNA vs NDAQ
+9.1%
+134.2%
-34.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 6mo.
| Period | Portfolio | NDAQ | Excess | Alpha |
|---|---|---|---|---|
| 1D | -3.4% | -0.9% | -2.5% | -3.6% |
| 7D | -10.1% | -1.6% | -8.5% | -10.4% |
| 30D | +126.7% | -1.5% | +128.2% | +125.6% |
| 3M | +184.1% | +8.0% | +176.1% | +175.6% |
| 6M | +143.3% | +7.7% | +135.6% | +135.1% |
| All | +143.3% | +9.1% | +134.2% | +135.1% |
Cumulative growth
Daily Returns
Daily percentage return beside NDAQ.
Daily Out/Under-Performance
Portfolio return minus NDAQ return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × NDAQ return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 6mo: compounded portfolio wealth divided by compounded NDAQ wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
6mo analysis · Full analysis span regression · 6 months rolling